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heterogeneous spectrum of diseases of the heart, including
the cardiomyopathies and the arrhythmic diseases in
structurally normal hearts, that is, channelopathies. With a
combined estimated prevalence of 3% in the general
population, these conditions represent a relevant
epidemiological entity worldwide, and are a major cause of
cardiacmorbidity andmortality in the young. Theextraordinary
progress achieved in molecular genetics over the last three
decades has unveiled the complex molecular basis of many
familial cardiac conditions, paving the way for routine use of
gene testing in clinical practice. In current practice, genetic
testing can be used in a clinically affected patient to confirm
diagnosis, or to formulate a differential diagnosis among
overlapping phenotypes or between hereditary and acquired
(nongenetic) forms of disease. Although genotype–
phenotype correlations are generally unpredictable, a precise
molecular diagnosis can help predict prognosis in specific
patient subsets and may guide management. In clinically
unaffected relatives, genetic cascade testing is recommended,
after the initial identification of a pathogenic variation, with the
aim of identifying asymptomatic relatives whomight be at risk
of disease-related complications, including unexpected
sudden cardiac death. Future implications include the
identification of novel therapeutic targets and development of
tailored treatments including gene therapy. This document1558-2027  2017 Italian Federation of Cardiology. All rights reserved.reflects the multidisciplinary, ‘real-world’ experience required
when implementing genetic testing in cardiomyopathies and
arrhythmic syndromes, along the recommendationsof various
guidelines.
J Cardiovasc Med 2017, 17:000–000
Keywords: arrhythmias, cardiomyopathies, genetic counselling, genetic
testing, massive sequencing
aGenetic Diagnostic Unit, Cardiomyopathies Unit, Careggi University Hospital,
Florence, bDepartment Molecular Medicine and Medical Biotechnologies, Italy
and Ceinge-Advanced Biotechnologies, University Federico II, Naples, Naples,
cBioinformatics Unit, Istituto Toscano Tumori, Hospital of Prato, Prato,
dDepartment of Cardiovascular, Neural and Metabolic Sciences, Center for
Cardiac Arrhythmias of Genetic Origin and Laboratory of Cardiovascular
Genetics, IRCCS Istituto Auxologico Italiano, San Luca Hospital, Milan;
Department of Molecular Medicine, University of Pavia, Pavia, eUSSD Laboratorio
Genetica Medica, ASST Papa Giovanni XXIII, Bergamo, fDivision of Cardiology,
Department of Emergency Medicine, Tor Vergata University of Rome, Rome,
gCardiovascular Pathology Unit, Department of Cardiac, Thoracic and Vascular
Sciences, University of Padua, Padua, hCentre for Inherited Cardiovascular
Diseases, IRCCS Foundation Policlinico San Matteo, Pavia, iCardiomyopathies
Unit, Careggi University Hospital, Florence and jDepartment of Cardiothoracic
Sciences, Campania University Luigi Vanvitelli, Caserta, Italy; Institute of
Cardiovascular Sciences, University College of London, London, UK
Correspondence to Francesca Girolami, BSc, Genetic Diagnostic Unit,
Cardiomyopathies Unit, Careggi University Hospital, Largo Brambilla 3, 50134
Florence, Italy
Tel: +39 0557945508; fax: +0557949686; e-mail: girolami.fra@gmail.com
Received 4 August 2017 Revised 30 September 2017
Accepted 28 October 2017AQ4Introduction
Inherited cardiac diseases comprise a wide and heteroge-
neous spectrum of diseases of the heart, including the
cardiomyopathies and the arrhythmic diseases in structur-
ally normal hearts, that is, channelopathies.1 With a com-
bined estimated prevalence of 3% in the general
population,1 these conditions represent a relevant epidemi-
ological entity worldwide, and are a major cause of cardiac
morbidity and mortality in the young. The extraordinary
progress achieved in molecular genetics over the last three
decades has unveiled the complex molecular basis of many
familial cardiac conditions, paving theway for routine use of
gene testing in clinical practice. According to the European
Society of Cardiology classification, cardiomyopathies are
divided into dilated (DCM), hypertrophic (HCM), arrhyth-
mogenic right ventricular (ARVC), restrictive andunclassified, although in practice there may be extensive
overlap between these phenotypes.2 The hypokinetic non-
dilated cardiomyopathyhasbeen recently added to theprior
major phenotypes.3 The American Heart Association
advanced a gene-based classification4 so that HCM was
viewedas a disease of the sarcomere5 andARVCas adisease
of intercellular junctions, caused by mutations in genes
encoding desmosomal proteins.6,7 The genetics of familial
DCM is far more heterogeneous: currently, DCM muta-
tions have been described in genes encoding cytoskeletal,
sarcomeric, desmosomal, nucleoskeletal, mitochondrial,
and calcium handling proteins.8
Additionally, sarcomere mutations have been identified
in association with more complex disorders of cardiac
structure and function, including restrictive physiology
and left ventricular noncompaction.4 In the samemanner,DOI:10.2459/JCM.0000000000000589
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of variants in the same genes (LMNA, FLNC, and desmo-
somal genes).7 Channelopathies, generally caused by
mutations in proteins constituting or regulating cardiac
ion channels, include the long-QT syndrome
(LQTS),the short-QT syndrome (SQTS), Brugada syn-
drome (BrS), and catecholaminergic polymorphic ven-
tricular tachycardia (CPVT).9 In this scenario, molecular
cardiology has become an important tool to investigate
the aetiology, pathogenesis, and development of inher-
ited cardiac disease, and is beginning to change clinical
practice. In current practice, genetic testing can be used
in a clinically affected patient to confirm diagnosis, or to
formulate a differential diagnosis among overlapping
phenotypes or between hereditary and acquired (nonge-
netic) forms of disease.10–15 Although genotype–pheno-
type correlations are generally unpredictable, a precise
molecular diagnosis can help predict prognosis in specific
patient subsets and may guide management.16–18 In
clinically unaffected relatives genetic cascade testing is
recommended, after the initial identification of a patho-
genic variation, with the aim of identifying asymptomatic
relatives who might be at risk of disease-related compli-
cations, including unexpected sudden cardiac death.19–21
Future implications include the identification of novel
therapeutic targets and development of tailored treat-
ments including gene therapy.
The document reflects the multidisciplinary, ‘real-world’
experience required when implementing genetic testing
in cardiomyopathies and arrhythmic syndromes, along
the recommendations of various guidelines.15,22,23 We
here address the analytical aspects of genetic testing,
the complex field of attribution of pathogenicity for each
mutation, the main aspects of genetic counselling, and
various related ethical issues.
Genetic testing
Traditional methods
Since the introduction of genetic testing in the clinical
practice of inherited cardiovascular diseases, the number
and size of genes investigated have increased dramati-
cally. Until 10 years ago, parallel mutation detection was
largely performed by PCR-based techniques such as
denaturing HPLC and high-resolution melting, both in
the research setting and in clinical practice.24,25 However,
their sensitivity for variant detection range from 95% to as
low as 80% and is highly dependent on adequate opti-
mization of the technique.26 Thus, although denaturing
HPLC and high-resolution melting techniques have
been widely used over the past years to perform genetic
test in the setting of inherited cardiomyopathies,27–29
they are now largely superseded.
Direct DNA sequencing, that is the process of determin-
ing the precise order of nucleotides within nucleic acid
fragment, is the gold standardmethod for the detection of
gene mutations. For the past 30 years the Sanger DNAsequencing technology, based on chain termination
method, has been the dominant approach, and remains
the test of choice in Mendelian diseases without genetic
heterogeneity.30 Sanger DNA sequencing, else known as
‘first generation’ sequencing, has enabled the identifica-
tion of genes currently known to cause inherited cardio-
vascular diseases, demonstrating high accuracy and
reproducibility. In the Heart Rhythm Society /European
Heart Rhythm Association expert consensus statement
on the state of genetic testing, Sanger sequencing was
referred as a high-sensitivity method for the identification
of mutations associated with cardiomyopathies and chan-
nelopathies.15 However, neither scanning techniques nor
sequencing are reliable in identifying medium/large
insertions or deletions. Therefore, an additional tech-
nique, such as quantitative PCR or multiplex ligation-
dependent probe amplification, is needed to assess gene
dosage.31–35
Massive parallel sequencing: the new standard
Despite its monumental accomplishments, Sanger
sequencing can only analyse one DNA segment at a time
and is thus laborious and time consuming, especially for
genetically heterogeneous diseases such as cardiomyop-
athies/channelopathies. Time and cost limitations have
therefore precluded its use for large-scale genome
sequencing, stimulating the advance of powerful new
technologies capable of delivering fast, less expensive,
and accurate genome information.36,37
The commercial launch of the first massively parallel
pyrosequencing platform in 2005 rapidly projected the
field in a new era of high-throughput genomic analysis,
currently referred to as next-generation sequencing
(NGS). Although NGS platforms differ in their hardware
configuration and sequencing chemistry, they share a
common technical paradigm: massively parallel sequenc-
ing of clonally amplified or single DNA molecules that
are spatially separated.38–41 Through iterative cycles of
polymerase-mediated nucleotide extensions (MiSeq, Ion
Personal Genome Machine) or, in one approach, through
successive oligonucleotides ligations (solid), it is now
possible to obtain sequence outputs in the range of
hundreds of megabases to gigabases38,39,42 (Fig. 1). In
the past decade several NGS platforms have been devel-
oped and today the Life Technologies (Carlsbad, Cali-
fornia, USA) Ion Torrent Personal GenomeMachine and
the Illumina (San Diego, California, USA) MiSeq and
NextSeq are the most commonly used platforms.43 Both
allow for simultaneous interrogation of multiple genes in
multiple samples by a single reaction. These strategies
have proven accurate and effective in detecting muta-
tions associated with Mendelian disease, both in the
research and clinical settings.41,44
The advent of high-throughput sequencing has pro-
duced a number of commercially available sequencing
options for genetic testing of cardiomyopathies, which
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(I) Extraction of genomic DNA. (II) Ligation of specific adaptor (oligonucleotides) to fragments of the DNA to be sequenced. (III) Fragments
amplification. (IIIa) The PGM system utilizes emulsion PCR to amplify single fragments onto microbeads, that will be loaded in the sequencing chip.
(IIIb) The MiSeq system utilizes bridge amplification to form template clusters on a flow cell. (IV) Sequencing. (IVa) The PGM gets sequence
information by detecting pH variations induced by the release of a hydrogen ion once a nucleotide is incorporated into a growing strand of DNA. (IVb)
MiSeq is based on the detection of fluorescence generated by the incorporation of fluorescently labelled nucleotides into the growing strand. Once
sequencing is complete, specific software process the raw data, to convert pH or fluorescence signals into actual sequence data.
AQ1include: targeted panels that range from 5 to 20 genes,
broad panels containing dozens of genes for a class of
traits such as pan-cardiomyopathy or pan-arrhythmia
(30–174 genes), whole exome sequencing (WES: about
20 000 genes), and whole genomes.45 The advantage of
more comprehensive tests is the potential for increased
sensitivity of variant detection. The major drawbacks
include costs, but mostly a huge increase in detection
of variants of unknown clinical significance, enhancing
the complexity of interpretation. Thus, a focused,
targeted approach remains the cornerstone of testing
in the clinical setting.46
Distinguishing pathogenic variants from
background noise
NGS platforms generate millions of short (50–250 bp)
sequence reads per run that must be processed by tailored
bioinformatics pipelines. Figure 2 show the workflow used
to sequencing and filtering the variants detected by NGS
strategy. After library preparation and sequencing, bioinfor-
matics analysis is performed. Bioinformatics analysis of data
includes mapping of short sequencing reads to a referencegenome by short read aligners,47,48 processing of alignment
through duplicated sequences removal, base quality recali-
bration and alignment correction,49,50 variant calling,49–51
and genomic and functional annotation of the variants.52–56
Annotation is the collection of all available information to
distinguish clinically relevant from common or private
variants. Typically, tens of thousands genomic variants
are identified by WES in a single patient. Annotation is
the process that helps genomic analysts and clinicians to
distil these huge amounts of data by using genomic and
functional information collected in biological and/or clinical
databases. The American College of Medical Genetics and
Genomics has emphasised the most important criteria to
establish causality of putativedisease-causingmutations are
minor allele frequency with a credible cut off of 0.01%,
cooccurrence with disease, in-silico pathogenicity scores,
and when possible familial cosegregation and functional
assays.57Therefore, annotation tools identifywhich variants
are reported in allele frequency databases, such as dbSNPs
(https://www.ncbi.nlm.nih.gov), 1000 Genome Project
(http://www.internationalgenome.org/), Exome Sequenc-
ing Project (http://evs.gs.washington.edu/EVS/),58–60 or
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Schematic workflow of a standard genetic analysis by next-
generation sequencing. NGS, next-generation sequencing; PGM,
personal genome machine. After genetic counselling, patient’s tissue
sample is collected. Depending on the most appropriate protocol
(targeted gene sequencing or whole exome sequencing), NGS
libraries are prepared and sequenced through a next generation
sequencers. Sequencing reads are evaluated through different
quality measures. Reads are aligned to the human reference genome
by a short read aligner. Resulting alignment is then processed for
sorting, indel realignment, and base quality recalibration and
eventually duplicates removal. Appropriate softwares can be used to
identify single nucleotide variants and small insertion/deletions.
Annotation of detected variants is performed by programs that
compute amino acid coding changes and annotate variants to allele
frequency, clinical, and functional prediction databases. To identify a
small set of rare, possibly pathogenic, variants, filtering of annotated
variants based on functional and allele frequency criteria is
performed. Next, prioritization strategies are aimed at identifying
clinically relevant variant(s). These can involve tailored interpretation
of variants or the use of appropriate computational methods.
Identified clinically relevant variants can be validated through
independent molecular techniques, such as Sanger sequencing.
Finally, a clinical report is prepared.Exome Aggregation Consortium61 (http://exac.broadinsti
tute.org/),Genome Aggregation Database,62 (http://gno
mad.broadinstitute.org) or NHLBI Trans-Omics for Preci-
sion Medicine program63 (https://www.nhlbi.nih.gov/
research/resources/nhlbi-precision-medicine-initiative/top-
med),which variants cause amino acid changes or generate a
stop codon, which fall within regions of DNA copy number
variations64 or conserved regions among numerous spe-
cies.65 Annotation tools are also able to predict the patho-
genicity of variants by bioinformatics tools such as SIFT66
and PolyPhen2,67 which predict the effect of an amino acid
substitution on the structure and function of a protein using
sequence homology; and by query clinical catalogues,
including the Human Gene Mutation Database,68 the
Online Mendelian Inheritance in Man,69 ClinVar,70 and
Catalogue of SomaticMutations inCancer,71with the aim to
highlight variants that are known to be associated with
certain phenotypes and/or diseases. Prioritization methods
are also useful in the research setting, to discover clinically
relevant variants or genes. Tools such as eXtasy,72 Topp-
Gene,73 and SUSPECTS74 are designed to identify, among
auser-definedgene list, those that aremore likely associated
with a certain disease, by exploiting the integration of
heterogeneous datasets, such as literature reports, expres-
sion, and functional data. According to these criteria, var-
iants can be classified as pathogenic, likely pathogenic,
variants of uncertain significance (VUS), or benign.
Functional assays
A reliable functional assay is generally recommended to
verify the biological effect of an unknown genetic varia-
tion. Patch clamp is the gold standard in studying the
electrophysiologic properties of mutated versus wild-
type cardiac channels.75,76 Cardiomyopathies provide a
particular challenge to establish causality for putative
disease-causing variants, because of the complexity to
assay the effect of genetic variants in human cardiac
structural proteins. Varieties of in-vitro and in-vivo tech-
niques have been used to verify the function of mutant
structural macromolecules.77–80 The stringency for
emphasizing relevant pathologic changes in an appropri-
ate model is addressing to use the induced pluripotent
stem cells to create an investigational tissue source from a
study participant harbouring the variant that has the same
genetic background.81,82 However, these techniques are
labour intensive and require highly skilled staff, therefore
are not readily applicable to large-scale approaches and
not feasible in a diagnostic setting.
Genetic counselling
The general goals of genetic counselling are to increase
patients’ knowledge and awareness about their disease
and its genetic aspects, and to ensure that patients can
control their feelings about their condition, resulting in
the ability to make autonomy choices for themselves and
their relatives. Discussions with the patient (and the
parents in the case of children) about the importance
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recommendation that information be shared with poten-
tially affected family members as appropriate, is a stan-
dard part of genetic counselling.
Genetic evaluation is indicated in paediatric and adult
patients with signs of systemic diseases, including facial
dysmorphisms, skeletal and cutaneous abnormalities,
mental retardation, delayed speech, sensorineural
deafness, skeletal myopathy, diabetes, to exclude genetic
syndromes, metabolic/infiltrative diseases, mitochon-
drial, and neuromuscular disease, as a cause of cardiomy-
opathies.
Informed consent
The process of educating a person about the test and
obtaining permission to carry out testing is called
informed consent. ‘Informed’ means that the person
has enough information to make an educated decision
about testing; ‘consent’ refers to a person’s voluntary
agreement to have the test done. In general, only adults
who are competent to make medical decisions for them-
selves can give informed consent. For children and others
who are unable to make their own medical decisions,
either parents or legal guardian must take responsibility.
The genetic counsellor, or trained healthcare profes-
sionals, discusses the test, answers the questions, and
obtains the consent. Several factors are commonly
included in the consent form: the general description
of the test, including the purpose and the condition for
which the testing is being performed; the biological
sample required for the analysis (for example, a blood
sample);what the test results mean, including positive
and negative results, and the potential for uninformative
results or false positives or false negatives results;
whether the results might provide information about
other family members’ health, including the risk of
developing a particular disease or the possibility of having
affected children; how and to whom test results should be
reported; what will happen to the test specimen after the
test is complete; and acknowledgement that the person
requesting testing has had the opportunity to discuss the
test with a healthcare professional. Furthermore, the
advent of new techniques, such as clinical WES, raises
the problem of incidental findings, that is, genetic results
that you aren’t looking for. Therefore, the patient must
be informed of this possibility and should express his/her
will whether to know or not such results. The patient and
the counsellor must sign the informed consent. It is
important to remind patient that, even after signing,
he may still opt out at any time, and that the informed
consent document is not a binding contract.
Genetic counselling in structural
Cardiomyopathies
HCM, DCM, ARVC, and left ventricular noncompaction
are the most frequent structural cardiomyopathies forwhich genetic test can be proposed as part of the diag-
nostic flow chart. The main genes involved in HCM,
DCM, and ARVC are summarized in Table 1. Inherited
cardiomyopathies generally show an autosomal
dominant, or less frequently an autosomal recessive or
X-linked pattern of inheritance and are characterized by a
large variable expressivity and age-dependent pene-
trance. Genetic test is recommended even in patients
with no family history of inherited cardiomyopathies or
SD, as this may simply reflect inaccuracies of family
history and screening, incomplete penetrance, or a
de-novo mutation in proband. In all structural cardiomy-
opathies risk of transmission is 50% at each pregnancy
and the knowledge of the disease-causing mutation is
crucial for family planning even though inheritance prob-
ability does not reflect ‘the risk’ of having the disease.
HCM is reviewed here as a paradigm of inherited car-
diomyopathies, although most considerations with regard
to gene testing also apply to the other conditions. It is the
most common monogenic cardiac disorder and a preva-
lent cause of sudden cardiac death in young people and
competitive athletes.15,83,84 The first-tier genetic test for
HCM patients includes the most commonly implicated
sarcomere protein genes (MYBPC3, MYH7, TNNT2,
TPM1, MYL2, MYL3, TNNI3, and ACTC1) with a diag-
nostic sensitivity of about 65% (Table 1).22 Patients
presenting features suggestive of specific genetic subsets
(i.e. Anderson–Fabry, Danon, Noonan/LEOPARD,
Friedreich’s ataxia, amyloidosis, mitochondrial diseases,
etc.) or that are negative at first-tier test, are candidates to
further testing to exclude rare phenocopies.
International position statements recommend genetic
test in HCM as a class I indication, based on the potential
clinical benefit and favourable cost-efficacy profile.22 The
main benefits of genetic testing for the proband include
the possibility of achieving a definitive diagnosis and the
identification/exclusion of few high-risk mutations or
complex genotypes (multiple mutations). These geno-
types are usually associated with severe disease expres-
sion, such as marked hypertrophy, premature heart
failure, and progression to the hypokinetic restrictive
stage.85 A recent meta-analysis based on a comprehensive
genotype–phenotype analysis reveals that HCM patients
show an earlier age at onset and a more severe phenotype
compared with patients without such mutations. Further-
more, patients with sarcomeric mutations are more sus-
ceptible to SCD in comparison with HCM patients
without sarcomere mutations. Although the great clinical
variability, even within families, suggests that therapeu-
tic choices should not be based on genotype, it seems
reasonable to include genetic findings in risk assessment,
especially in patients with borderline risk for SCD by
conventional clinical scoring systems.86
A second-tier test, based on extended gene panels, may
distinguish rare HCM phenocopies, which need to be
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Table 1 Main genes involved in cardiomyopathies (hypertrophic
cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right
ventricular cardiomyopathy)a
Hypertrophic cardiomyopathy
Sarcomeric genes/phenocopy genes
Gene Frequency (%)
b-myosin heavy chain MYH7 20–30
Cardiac myosin-binding protein C MYBPC3 30–40
Regulatory myosin light chain MYL2 2–4
Cardiac troponin T TNNT2 3–5
Cardiac troponin I TNNI3 <5
a-tropomyosin TPM1 <1
a-cardiac actin ACTC1 <1
Essential myosin light chain MYL3 <1
Galactosidase, a GLA <1 Fabry disease
Lysosomal-associated
membrane protein 2
LAMP2 <1 Danon disease
Protein kinase, AMP activated,
g2 subunit
PRKAG2 <1 Wolff–Parkinson–
White syndrome
Dilated cardiomyopathy
Sarcomeric/Zdisc genes
Gene Frequency (%)
Titin TTN 15–25
b-myosin heavy chain MYH7 3–4
Cardiac troponin T TNNT2 3
a-tropomyosin TPM1 1–2
a-cardiac actin ACTC1 <1
Cardiac troponin I TNNI3 <1
Cardiac troponin C TNNC1 <1
?-actinin 2 ACTN2 <1
Telethonin TCAP <1
Cardiac ankyrin repeat protein ANKRD1 <1
Cypher/ZASP LDB3 <1
Muscle LIM Protein CSRP3 <1
Other genes (cytoskeletal/desmosomal/nuclear envelope/dystrophin complex/
nucleus/ion channels/sarcoplasmic reticulum, and cytoplasm)
Gene Frequency (%)
Lamin A/C LMNA 4–8
Type V voltage-gated cardiac Na Channel SCN5A 2–3
Desmoplakin DSP 2
RNA-binding protein 20 RBM20 2
Metavinculin VCL 1
Filamin C FLNC 1
Dystrophin DMD <1
Desmin DES <1
Sulfonylurea receptor 2A ABCC9 <1
D-Sarcoglycan SGCD <1
Phospholamban PLN <1
Arrhythmogenic right ventricular cardiomyopathy
Desmosomal genes/other genes (nuclear envelope/intermediate filament/growth
factor)
Gene Frequency (%)
Plakophilin-2 PKP2 30–40
Desmoglein-2 DSG2 5–20
Desmoplakin DSP 10–20
Desmocollin-2 DSC2 1–2
Junction plakoglobin JUP 1–2
Transmembrane protein 43 TMEM43 <1
Transforming growth factor 3 TGFB3 <1
Desmin DES <1
aT-catenin CTNNA3 <1
Cadherin C CDH2 <1
a
OMIM (www.omim.org); GeneCards (www.genecards.org).diagnosed at an early stage. Several clinical red flags may
suggest an alternative diagnosis to ‘classic’ HCM. These
include an X-linked or autosomal recessive pattern of
inheritance, peculiar ECG signs, extracardiac manifesta-
tions, and so on. Diagnosis is important because of
management implications (e.g. availability of enzyme
replacement therapy in Fabry disease and early need
for cardiac transplantation in Danon disease). Once a
causative mutation is found in the proband, genetic
testing of first-degree family members, leading to cascade
genetic screening, is strongly indicated (class I), to pro-
mote preclinical diagnosis and prevention in affected
family members and implement follow-up. Relatives
found not to carry the mutation do not require further
clinical workup, provided that the causative role of the
mutation is well established.
Genetic counselling in channelopathies
LQTS, BrS, CPVT, and SQTS are the main channelo-
pathies for which expert consensus documents have been
published, providing clear recommendation on when to
perform a molecular screening as part of the diagnostic
assessment and on which genes.15,87 These recommen-
dations are based on two major considerations, the impact
of genetic testing on clinical management and the yield of
the test (that for clinical purposes should be focused
exclusively on the major genes). These two concepts
are also at the basis of a good genetic counselling. In
probands with LQTS and CPVT, genetic testing has a
class I indication and a disease-causing mutation can be
identified in 70–80% and 60–70% of probands, respec-
tively.15,88 The identification of a disease-causing muta-
tion should be perceived positively by an adequately
informed patient, as a means to improve clinical manage-
ment. This is impressively shown in LQTS, because of
the fact that arrhythmic triggers, response to therapy and
prognosis differ based on the disease-causing gene89 and
sometimes to the specific mutation.90 As an example,
patients with a KCNQ1 mutation (LQT1 patients) are at
higher risk during physical activity, but are very well
protected by b blockers; whereas patients with KCNH2
mutations (LQT2 patients) are known to be at higher risk
in the presence of sudden noises and in the postpartum
period, and their response to b blocker therapy is reason-
ably good.89 As a consequence, LQT2 are advised not to
keep telephones or loud alarm clocks making loud noises
in the bedroom and, in the case of a women LQT2
mother, we prompt the father to take care of nocturnal
parental duties. In LQT3 harbouring a SCN5A mutation,
a gene-specific therapy with sodium channel blockers
may be considered in addition to b blockade.91 Further-
more, specific genes, as genes encoding for the calmodu-
lin protein (CALM 1–3), are associated with a very severe
phenotype and poor response to available therapies.92 At
variance with LQTS and CPVT, in SQTS a disease-
causing mutation is identified in less than 5–10% of
probands and the impact on the clinical management
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ommendation. In these conditions BrS represents and
intermediate situation, with class IIa recommendation.15
A very important issue that should be discussed with the
patient before genetic counselling is the impact of the
genetic test result on the clinical management of the
entire family. In all channelopathies, as in structural
cardiomyopathies, risk of transmission is 50% at each
pregnancy and the knowledge of the disease-causing
mutation could theoretically allow the selection of the
unaffected embryos. However, this information, which
clearly has a strong ethical impact, should be given
together with the risk of the disease in children and
adults and with the information about how treatable
the disease is and which is the impact of the disease
on a growing child. The identification of a disease-caus-
ing mutation in the proband should trigger cascade test-
ing in the whole family (class I indication for all
channelopathies).
When, where, and how to perform genetic
testing
When
Genetic testing should be offered to index patients who
fulfil diagnostic criteria for genetic cardiovascular disease.
A comprehensive clinical evaluation should precede
genetic testing, as a precise clinical diagnosis (or reason-
able suspicion) is extremely important in guiding the type
of test on which needs to be performed. As discussed,
testing is recommended in family members only when a
genemutation disease-causingmutation has been already
identified.93 Careful consideration is needed when family
members are asymptomatic children or adolescents.93
Genetic testing is recommended in children under the
age of 4 years on in families with channelopathies and
after the age of 10 years in families with structural
progressive cardiomyopathies, unless conditions of anxi-
ety because of uncertainty, and the need of a realistic
lifestyle planning and clinical follow-up might advise
earlier testing.22
In the recent years, there has been an increasing empha-
sis on the role of genetic testing of DNA obtained at
autopsy (also called ‘molecular autopsy’). In this setting,
pathologists play an important role in the identification of
families with hereditary conditions, by reporting whether
it is recommended to refer first-degree family members
for clinical screening and/or to perform additional post-
mortem genetic testing. According to the European Soci-
ety of Cardiology guidelines,94 targeted postmortem
genetic analysis of potentially disease-causing genes
should be considered in all SD victims in whom a specific
inheritable channelopathy or cardiomyopathy is sus-
pected (class of recommendation IIa and level of evi-
dence C). However, the SD guidelines of the Association
for European Cardiovascular Pathology recommend that
preliminary genetic counselling of family members iscarried out before performing postmortem genetic testing
(Basso et al. Virchow Arch 2017 submitted). Furthermore,
the problem of costs, not yet supported by the NHS for a
dead person in Italy, is still a major issue.
Where?
The complexity of diagnosing inherited cardiovascular
diseases highlights the importance of dedicated cardioge-
netic services. DNA testing should be performed in certi-
fied laboratory and counselling should be performed by
trained healthcare professionals, working within multidis-
ciplinary teams to help patients understand and manage
the psychological, social, professional, ethical, and legal
implications of genetic disease. Information should be
provided on existing legislative protection for discrimina-
tion based on genetic testing, including discussion of areas
that are not protected. These laws vary from country to
country. Psychological support can be provided, especially
with posttest counselling, to help individual scope with
anxiety associated with the disease or genetic result. A
comprehensive evaluation of patients and families should
be undertaken in referral institutions providing the exper-
tise of cardiologists, electrophysiologists, radiologists,
geneticists, pathologists, psychologists, and molecular
biologists as well as experts in bioinformatics, ethics,
and health services research. An interdisciplinary team
with synergistic areas of expertise will ensure clinical
diagnosis, provide optimal counselling, and management
of families with hereditary cardiovascular conditions. The
management of patients with cardiovascular diseases
includes expert judgement regarding indications, type,
and interpretation of genetic testing.
How?
In general, genetic testing are a free choice of patients and
are never a mandatory step in the clinical management of
the patients. Pretest counselling is necessary to provide
patients with the relevant information (benefits and lim-
itations of the test and the possible consequences of the
test results) and generate realistic expectations allowing a
free and aware choice of the patient. Moreover, pretest
counselling is essential to accurately collect information on
family and clinical history and to assess the presence and
severity of risk factors. At posttest counselling, genetic
results should be discussed directly with the patient in
presence of a cardiologist and a geneticist. Postcounselling
has themain objective to help clinicians to interpret results
based on familial and clinical evidences.
How to interpret a genetic result
The results of genetic testing can be complex. Although a
result may be categorized as positive, negative, or uncer-
tain, its clinical significance strongly depends on the
patient’s personal and family history, and the clinical
context should never be forgotten when interpreting
the variants identified.
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Table 2 When, where, how to perform genetic testing in patients/families affected by inherited cardiac disease
When Where How
Genetic testing should be offered to index
patients who fulfil diagnostic criteria for familial
cardiovascular disease In dedicated cardiogenetic services
Genetic tests are usually performed on DNA
extracted for a blood sample
Probands with a precise clinical diagnosis (or
reasonable suspicion)
Family members only when a gene mutation has
been already identified
Careful consideration is needed when family
members are asymptomatic children or
adolescents
DNA testing should be performed in certified
laboratory
Counselling should be performed by trained
healthcare professionals working within
multidisciplinary teams
Pretest counselling should be offered to:
draw family pedigrees,
collect information on family history, and
help patients comprehend the procedure, benefits and
limitations of the test and the possible consequences of the
test results
Posttest counselling should be offered: to discuss genetic
results directly with the patient in presence of a cardiologist
and a geneticistPositive results
If the genetic test result is positive, this means that a rare
variant compatible with the presenting diagnosis was
identified and that its pathogenicity is clear and well
documented. If the purpose was to diagnose or confirm
the genetic aetiology of a specific disease or condition, a
positive result will help to determine the right treatment,
management, and follow-up plan. If the aim of genetic
testing was to find out if an individual is carrying an
altered gene that could cause disease (presymptomatic
and predictive testing), and the test is positive, the risk of
actually developing the disease will depend on multiple
factors, many not yet known, and frequently different
according to the specific inherited cardiac disease. In
other words, in the case of cardiomyopathies a positive
test does not necessarily mean that the study participants
will manifest the disorder. For example, having a familial
mutation in HCM gene means that there is a high risk of
developing the disease at some point in life, but neither
its actual occurrence nor its severity may be predicted. In
case of channelopathies, having the genetic defect means
that the disease is there and therefore preventive strate-
gies should be established. For example, having a familial
mutation in a LQTS gene, means being at higher risk of
SCD even if the basal ECG shows normal values. There-
fore, lifestyle changes should be recommended and b
blocker therapy may be indicated.
Negative results
A negative result in the probands means that a genetic
alteration was not detected by the test. But a negative
result does not guarantee that the disease is not genetic.
The accuracy of genetic tests to detect alterations varies
depending on the condition being tested for. Genetic
testing may not be able to detect all genetic defects
causing a genetic disease as this is an evolving field. A
negative result today may be positive in the next future.
On the other hand, in family members being found not to
carry the harmful gene alteration, previously identified in
their family, the risk to develop the hereditary cardiomy-
opathy may be virtually excluded: they may feel less
anxious, have a better quality of life and may also benefit
from the knowledge that they have not passed the gene
alteration onto their children.Inconclusive results
In some cases, a genetic test may not be able to provide
helpful information about the genetic aetiology of the
disease. Everyone has variations in a multitude of genes,
and very often, these variations do not affect health.
Sometimes it can be difficult to distinguish between a
disease-causing gene alteration from ‘the background
noise’, the so called VUS, which means that although
the testing laboratory detected a DNA alteration, there
was not enough evidence to classify that alteration as
deleterious or neutral, therefore the variant has an uncer-
tain clinical significance. In these situations, follow-up
testing may be necessary, such as the clinical and genetic
characterization of other family members. The VUS
classification is the subject of international efforts,
although there remain no universally accepted methods
to establish pathogenicity and to report VUS results. The
progression of knowledge, the continuous increase in
related disease variants worldwide, the availability of
largest families, the ability to perform functional studies,
and so on can modify the actual weight of a single variant
in the causal relation with a specific disease. Moreover, a
VUS should not be used in clinical decision-making
before follow-up testing is completed (Table 2).
Ethical issues in genetics: bioethics
considerations
There are several aspects of genetic testing that may lead
to ethical dilemmas, some inherent to the characteristics
of a specific test (e.g. the limitations of what genetic
testing can provide in specific clinical situations) other
inherent to genetic condition/results (privacy, biological
identity, familial implications, etc.). In general, genetic
testing enhances phenotypic screening and clinical sur-
veillance, and for any clinical purpose should be tied to
the availability of intervention, including counselling,
lifestyle changes, reproductive decision-making, and pre-
natal diagnosis. The physician ordering genetic test has
the responsibility to use it correctly. Therefore, it is
preferred that the patient refers to a geneticist with
experience in the field of cardiomyopathies or channe-
lopathies, who is aware of when it is appropriate to test
and which particular test to order, what information the
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how to interpret positive, negative, and uncertain results
in light of the patient’s medical or familial history. The
geneticist may also suggest in-depth testing, when nec-
essary and based on the progress of technology and
scientific knowledge. Testing of children presents
unique issues in counselling and consent. In general,
there are two extreme situations, one when the child is
suffering from a genetic disease and genetic testing
enters the path to achieving a diagnosis (diagnostic test-
ing); the other when the child is apparently healthy but
belongs to a family with a genetic disease that manifest
mainly, but not always, in adulthood (predictive testing).
The latter case opens ethical dilemmas and the physician
should balance the rights of the parents to have informa-
tion that can optimize the ongoing healthcare of their
children against the rights of the children to have their
best interest protected. The fundamental problem is
implicit in the genetic characteristics of these diseases
(variable penetrance and expressivity) and, conse-
quently, in low predictive power per se of the genetic
test. In this scenario, integration between clinical data
(i.e. age at onset and severity of symptoms in the rela-
tives), family history (positive or negative for sudden
death) and genetic results (presence of specific ‘malig-
nant’ mutations) can drive the choice. If the child belong-
ing to a cardiomyopathy – or channelopathy – family
enrols in a competitive sport, the genetic test should be
strongly considered.
Conclusion
Molecular cardiology has become an important tool to
study and understand the aetiology, pathogenesis, and
development of familial cardiomyopathies and channe-
lopathies and is beginning to change clinical practice.
Advances in contemporary DNA sequencing methodol-
ogy have made gene-based diagnosis increasingly feasi-
ble in routine clinical practice, but this should not occur at
the expense of clinical accuracy. Future efforts should be
aimed at promoting awareness of inherited cardiovascular
diseases among community-based cardiologist and pri-
mary care physicians, as well as establish high-standard
multidisciplinary referral teams on a regional and national
level, to guarantee the best possible use of genetic testing
in patients and their families.
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